REGN Regeneron Pharmaceuticals Inc.

Nation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search

Nation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search

The Regeneron Science Talent Search Honors America’s Brightest Young Scientists Advancing Discovery and Innovation

TARRYTOWN N.Y. and WASHINGTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- (the Society) and today announced the top 40 finalists in the 2026, America’s oldest and most prestigious science and math competition for high school seniors.

Key Takeaways:

  • The Regeneron Science Talent Search 2026 finalists represent 35 schools across 15 states. They are competing for more than $1.8 million, with a top prize of $250,000 to further their scientific education.
  • 40 finalists were chosen from 300 top scholars, and more than 2,600 total entrants were selected based on the originality and creativity of their scientific research, as well as their achievement and leadership both inside and outside the classroom.
  • Finalists will participate in a week-long competition from March 5-11, 2026, engaging in a rigorous judging process and competing for awards that recognize their excellence and can be used toward their education.
  • They will also have an opportunity to interact with leading scientists and share research with the public on March 8, 2026.
  • The top 10 Regeneron Science Talent Search 2026 winners will be announced during an awards ceremony on March 10, streamed live from Washington D.C.
  • For a list of this year’s finalists, see here: .

In its 85th year, the competition continues to spotlight exceptional young scientists whose technical excellence and leadership drive meaningful impact. Its alumni include 13 Nobel laureates, 23 MacArthur Fellows, eight Breakthrough Prize winners, and founders of influential science-driven companies such as Regeneron.

“My own scientific journey can be traced back to my experience with the Science Talent Search, which profoundly shaped who I am today. Participating in and becoming a winner of STS gave me the confidence to dedicate my life to science and the pursuit of inventing medicines that improve people’s lives,” said George D. Yancopoulos, M.D., Ph.D., co-Founder, co-Chairman, President, and Chief Scientific Officer at Regeneron, and a 1976 STS Winner. “Today, Regeneron helps millions of people around the world facing serious diseases, which is a testament to what is possible when young scientific talent is nurtured. I see that same potential to transform our world in these finalists, and I eagerly await their future contributions to science and humanity.”

Finalist research projects cover 16 categories, from Computer Science to Environmental Science. Other finalists chose to focus on Behavioral Sciences. The top 4 categories among finalist projects this year are:

  1. Computer Science
  2. Computational Biology and Bioinformatics
  3. Mathematics
  4. Medicine and Health

“We are immensely proud to celebrate this extraordinary class of Regeneron Science Talent Search finalists and their remarkable achievements,” said Maya Ajmera, President and CEO of Society for Science and Executive Publisher of Science News. “As they build on a powerful 85-year legacy of scientific innovation, they are propelled by the strength and support of a dynamic scientific community.”

What’s Next: Important Dates for 2026

  • Regeneron STS Finalists Week: March 5-11, 2026
  • Public Exhibition of Projects: March 8, 2026
  • Winners Announced at Awards Ceremony: March 10, 2026

Resources:

What is the Regeneron Science Talent Search?

The Regeneron Science Talent Search, a program of Society for Science since 1942, is the United States’ oldest and most prestigious science and math competition for high school seniors. Each year, more than 2,000 student entrants submit original research in critically important scientific fields of study and are judged by leading experts in their fields. Unique among high school competitions in the U.S. and around the world, the Regeneron Science Talent Search focuses on identifying, inspiring and engaging the nation’s most promising young scientists who are generating innovative solutions to solve significant global challenges through rigorous research and discoveries. It provides students with a national stage to present new ideas and challenge conventional ways of thinking.

For over eight decades, the Science Talent Search has rewarded talented high school seniors who dedicate countless hours to original research projects and present their results in rigorous reports that resemble graduate school theses. Collectively, STS alumni have received millions of dollars in scholarships and gone on to be awarded Nobel Prizes, Fields Medals, MacArthur Fellowships and numerous other accolades.

What is Regeneron’s role?

In 2017,  became only the third sponsor of the Science Talent Search, with a 10 year 100 million commitment to help reward and celebrate the best and brightest young minds and encourage them to pursue careers in STEM as a way to positively impact the world. Throughout our partnership, Regeneron nearly doubled the overall award distribution to $3.1 million annually, increasing the top award to $250,000 and doubling the awards for the top 300 scholars to $2,000 and their schools to $2,000 for each enrolled scholar to inspire more young people to engage in science.

Learn more at .

What is Society for Science?

Society for Science is a champion for science, dedicated to promoting the understanding and appreciation of science and the vital role it plays in human advancement. Established in 1921, Society for Science is best known for its award-winning journalism through Science News and Science News Explores, its world-class science research competitions for students, including the Regeneron Science Talent Search, the Regeneron International Science and Engineering Fair and the Thermo Fisher Scientific Junior Innovators Challenge, and its STEM Outreach programming that seeks to ensure that all students have an opportunity to pursue a career in STEM. A 501(c)(3) membership organization, Society for Science is committed to inform, educate and inspire. Learn more at and follow us on Facebook, Twitter, Instagram, and LinkedIn.

What is Regeneron?

(NASDAQ: REGN) is a leading biotechnology company that invents, develops, and commercializes potentially life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious diseases, to foster a culture of integrity and excellence, and to build sustainable communities. Our most significant philanthropic investments are in science education, a commitment we call – our collection of programs and partnerships, including the (STS) and the , that fuel future scientific innovators to pursue bold ideas and advance world-changing solutions. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro bono, and matching gift programs. We are proud to be recognized on the Dow Jones Sustainability World Index and the Civic 50 list of the most “community-minded” companies in the United States.

For more information, please visit or follow Regeneron on , , or .

Media Contacts

Gayle Kansagor, Society for Science

703-489-1131,

Tina Parisi Tuttle, Regeneron

914-847-3511,  



EN
21/01/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Regeneron Pharmaceuticals Inc.

 PRESS RELEASE

Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spo...

Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating hives and recurring itch in young children TARRYTOWN, N.Y. and PARIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and...

 PRESS RELEASE

Regeneron Renews Sponsorship of the Regeneron Science Talent Search Th...

Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders Key Takeaways: Regeneron will extend its title sponsorship of the Regeneron Science Talent Search (STS) for a second decade, continuing its partnership with Society for Science to support the United States’ oldest and most prestigious science and mathematics competition for high school seniorsSince the start of Regeneron’s sponsorship in 2017 through this year’s STS, Regeneron and the Society have engaged an...

 PRESS RELEASE

Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medic...

Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS) Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared to placebo AFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring surgery with high rates of post-operative recurrence Dupixent is now approved in the U.S. to treat nine distinct diseases driven ...

 PRESS RELEASE

Garetosmab Biologics License Application Accepted for FDA Priority Rev...

Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability  If approved, garetosmab would be the first and only available treatment shown to reduce the number and volume of new heterotopic bone lesions in adults with FOP TARRYTOWN, N.Y., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) toda...

Regeneron Pharmaceuticals Inc: 2 directors

Two Directors at Regeneron Pharmaceuticals Inc sold/sold after exercising options 2,136 shares at between 778.516USD and 778.526USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary tr...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch